IP Library Granted Patent US 9,545,367
Granted Patent B2
US 9,545,367 · App. 14/700,661 · Granted Jan 17, 2017

Cosmetic use of N-heteroarylbisamide analogs and related compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,545,367
App. No.
14/700,661
Granted
Jan 17, 2017
Kind
B2
Abstract

Cosmetic and dermatological compositions comprising N-heteroarylbisamide analogs and methods of using such compositions to impart anti-aging benefits to the skin and/or improve skin conditions resulting from reduced collagen and hyaluronic acid production are disclosed. The N-heteroarylbisamides are believed to stimulate collagen and hyaluronic acid production and restore or maintain homeostasis for these compounds.

Claims (60)

1. A method for improving the aesthetic appearance of human skin comprising topically applying to an area of the skin in need thereof an amount of a cosmetic composition comprising a cosmetically acceptable vehicle and a dermatologically effective amount of a N-heteroarylbisamide of formula I:

where:

Q is N or C;

R, R 2 , R 2 , R 3 , R 4 and R 6 are independently H, C 1 -C 8 alkyl, heteroalkyl, alkoxyalkyl, heteroalkoxyalkyl, C 3 -C 8 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyl-aryl, heteroalkyl-aryl, aryl-alkyl, and/or heteroaryl-alkyl; and

R 1 and R 5 are independently H, C 1 -C 8 alkyl, heteroalkyl, alkoxyalkyl, heteroalkoxyalkyl, C 3 -C 8 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyl-aryl, heteroalkyl-aryl, aryl-alkyl, and/or heteroaryl-alkyl or WR wherein W is CO, CO 2 , CONH, SO 2 , PO 3 , or CH(Oalkyl) 2 ;

and n is 3.

2. The method according to claim 1 , wherein the skin enhancement is an increase in the production of procollagen or collagen, and the aesthetic improvement is selected from the group consisting of:

(a) treatment, reduction, and/or prevention of the appearance of fine lines or wrinkles,

(b) improvement of the skin's thickness, plumpness, and/or tautness;

(c) improvement in skin barrier repair and/or function;

(d) improvement in appearance of skin contours;

(e) increase in skin elasticity and/or resiliency;

(f) treatment, reduction, and/or prevention of skin sagging;

(g) smooth scars and stretch marks; and/or

(h) reduction in pore size.

3. The method according to claim 1 , wherein the skin enhancement is an increase in the production of hyaluronic acid and the aesthetic improvement is selected from the group consisting of:

(a) improvement in the skin's suppleness, softness, tone, radiance, and/or clarity;

(b) improvement in skin texture and/or promotion of retexturization;

(c) restoration of skin luster and/or brightness;

(d) replenishment of essential nutrients and/or constituents in the skin; and/or

(e) improvement of skin moisturization and/or complexion.

4. The method according to claim 1 , wherein the skin enhancement is the modulation of fibroblasts and the aesthetic improvement is selected from the group consisting of:

(a) increase in the production of structural proteins and glucosaminoglycans;

(b) improvement in the structure of collagen;

(c) homoeostasis of structural protein and glucosaminoglycans;

(d) down-regulation of cytokine production;

(e) increased activation of fibroblasts to fibrocytes;

(f) increase in the viability and/or function of fibroblasts;

(g) improvement in maintenance and remodeling of elastin; and/or

(h) improvement in skin barrier repair and/or function.

5. The method according to claim 1 , wherein the skin enhancement is the modulation of kertinocytes and the aesthetic improvement is selected from the group consisting of:

(a) improve the viability and/or function of the keratinocytes

(b) down-regulate the production of inflammatory factors and/or cytokines;

(c) improve skin barrier repair and/or function;

(d) improve thickness of the epidermis;

(e) improve uniformity of epidermal cells;

(f) improvement in pigmentation; and/or

(g) smooth scars and stretch marks.

6. The method of claim 1 , wherein the skin enhancement is improving and maintaining the quality and viability of the extracellular matrix and the aesthetic improvements is selected from the group consisting of:

(a) treatment, reduction, and/or prevention of the appearance of fine lines or wrinkles;

(b) improvement in the skin's thickness, plumpness, and/or tautness;

(c) improvement in skin barrier repair and/or function;

(d) improvement in appearance of skin contours;

(e) increased skin elasticity and/or resiliency;

(f) treatment, reduction, and/or prevention of skin sagging;

(g) smoothing scars and stretch marks;

(h) reduction of pore size;

(i) improvement in the skin's suppleness, softness, tone, radiance, and/or clarity;

(j) improvement in the skin texture and/or promotion of its retexturization;

(k) restoration of skin luster and/or brightness;

(k) replenishment of essential nutrients and/or constituents in the skin; and/or

(l) improvement in skin moisturization and/or type.

7. The method according to claim 1 , wherein the skin enhancement is improving and maintaining the quality and viability of the epidermis and the aesthetic improvement is selected from the group consisting of:

(a) improvement in skin barrier repair and/or function;

(b) improvement of thickness of the epidermis;

(c) improvement in uniformity of epidermal cells;

(d) improvement in pigmentation; and/or

(e) smoothing scars and stretch marks.

8. The method of claim 1 wherein the dermatologically effective amount of the cosmetic composition is applied to the area of skin in need thereof for a time sufficient to improve the area of skin's aesthetic appearance.

9. The method according to claim 8 , wherein the composition is applied to said skin at least once daily for a period of at least four weeks.

Assignments (2)
SECURITY INTEREST Recorded Nov 14, 2019
From: AVON PRODUCTS, INC.
To: CITIBANK, N.A., LONDON BRANCH
Reel/Frame 051032/0210 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 30, 2015
From: PARIMOO, SATISH; ILAYA, NANCY T.; LYGA, JOHN W.
To: AVON PRODUCTS, INC.
Reel/Frame 035553/0312 →